JP2012523432A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523432A5
JP2012523432A5 JP2012504890A JP2012504890A JP2012523432A5 JP 2012523432 A5 JP2012523432 A5 JP 2012523432A5 JP 2012504890 A JP2012504890 A JP 2012504890A JP 2012504890 A JP2012504890 A JP 2012504890A JP 2012523432 A5 JP2012523432 A5 JP 2012523432A5
Authority
JP
Japan
Prior art keywords
tissue
compound
oxygen atom
transplant
organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012504890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523432A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030556 external-priority patent/WO2010118334A1/en
Publication of JP2012523432A publication Critical patent/JP2012523432A/ja
Publication of JP2012523432A5 publication Critical patent/JP2012523432A5/ja
Pending legal-status Critical Current

Links

JP2012504890A 2009-04-09 2010-04-09 虚血再灌流に関係する浮腫を治療する方法 Pending JP2012523432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16808909P 2009-04-09 2009-04-09
US61/168,089 2009-04-09
PCT/US2010/030556 WO2010118334A1 (en) 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion

Publications (2)

Publication Number Publication Date
JP2012523432A JP2012523432A (ja) 2012-10-04
JP2012523432A5 true JP2012523432A5 (cg-RX-API-DMAC7.html) 2013-05-16

Family

ID=42936599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504890A Pending JP2012523432A (ja) 2009-04-09 2010-04-09 虚血再灌流に関係する浮腫を治療する方法

Country Status (14)

Country Link
US (1) US20120064044A1 (cg-RX-API-DMAC7.html)
EP (1) EP2416651A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012523432A (cg-RX-API-DMAC7.html)
KR (1) KR20120005025A (cg-RX-API-DMAC7.html)
CN (1) CN102458113A (cg-RX-API-DMAC7.html)
AU (1) AU2010233151A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1010516A2 (cg-RX-API-DMAC7.html)
CA (1) CA2757998A1 (cg-RX-API-DMAC7.html)
EA (1) EA201101349A1 (cg-RX-API-DMAC7.html)
IL (1) IL215604A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011010616A (cg-RX-API-DMAC7.html)
SG (1) SG175133A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010118334A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107815B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126822A2 (en) 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
EP2681314B1 (en) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
WO2019246264A1 (en) 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2021097345A1 (en) * 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05139992A (ja) * 1991-11-13 1993-06-08 Ajinomoto Co Inc ヒトadfを含有する臓器保護剤
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7960522B2 (en) * 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2004085396A1 (ja) * 2003-03-26 2004-10-07 Mitsubishi Pharma Corporation 虚血再灌流障害の予防または治療剤、臓器保存剤およびスクリーニング方法
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
AU2008285626B2 (en) * 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
WO2009126822A2 (en) * 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation

Similar Documents

Publication Publication Date Title
DE602004002087T2 (de) Bis(thio-hydrazid amid) verbindungen zur behandlung von mehrfach resistentem krebs
TW200817371A (en) Compounds for treating proliferative disorders
Wu et al. A comparison of 2 types of chest compressions in a porcine model of cardiac arrest
JP2014531434A5 (cg-RX-API-DMAC7.html)
JP5631327B2 (ja) 増殖性障害を治療するための化合物
AU2007288340A1 (en) Bis (thiohydrazide amides) for treating melanoma
JP2014532716A5 (cg-RX-API-DMAC7.html)
EP3563873A1 (en) Application of combination of polyethylene glycol and local anesthetic in non-narcotic analgesia
MXPA05012392A (es) Tratamientos de ansiedad con ziprasidona.
RU2008139988A (ru) Применение производных 3,5-втор-4-норхолестана для получения лекарственного средства-цитопротектора
IL255694A (en) Preparation for the treatment of tissue damage
JP2014500280A5 (cg-RX-API-DMAC7.html)
RU2008152746A (ru) Лечение ишемических заболеваний с применением эритропоэтина
RU2007101238A (ru) Пептидные агонисты вазопрессинового рецептора
JP2023154006A (ja) 細胞外マトリクスの合成を促進するグルコサミンのアミノ酸誘導体、及びこれを含む医薬組成物
JP2011516572A (ja) アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法
RU2001104454A (ru) Производные имидазола с бифенилсульфонильным замещением, способ их получения, их применение в качестве лекарственного средства или средства для диагностики, а также содержащее их лекарственное средство
RU2013130028A (ru) Новые производные оксадиазола в качестве модуляторов рецептора сфингозин 1-фосфата (s1p)
Wen et al. A simple technique for a new working heterotopic heart transplantation model in rats
JP2021504403A5 (cg-RX-API-DMAC7.html)
TW201521577A (zh) 用於增加器官及組織保存溶液之氧含量、安定性及保存壽命的含聚(0-2-羥乙基)澱粉調配物
JP2017533928A5 (cg-RX-API-DMAC7.html)
JP2002513785A5 (cg-RX-API-DMAC7.html)
White et al. Impact of initial reperfusion temperature on the functional recovery of DCD hearts
RU2133612C1 (ru) Способ восстановления сократительной функции сердца после кардиоплегии с антагонистами кальция в эксперименте